Gain Therapeutics To Participate At Drug Discovery Innovation Programme 2025

(MENAFN- GlobeNewsWire - Nasdaq) BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the“Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric, small-molecule therapies, today announced that Dr. Rinaldo Montalvão, Director of Artificial Intelligence at Gain Therapeutics, will deliver a talk at the WORLD BI sponsored Drug Discovery Innovation Programme (DDIP) 2025, being held September 25^th -26^th in Barcelona, Spain.

Details on the talk are as follows:

Track: AI and Automation in Drug Discovery

Title:“Transforming Drug Discovery: Generative Models and Electrostatic Complementarity”

Date: Friday, September 26, 9:20am CEST

About WORLD BI and DDIP 2025

WORLD BI connects global leaders through conferences that deliver value to hundreds of delegates each year. The events allow for networking with industry decision-makers to share knowledge, and spark new ideas.

World BI delivers Drug Discovery Conferences for scientists, sponsors, engineers, and exhibitors from the pharma, biotech, life sciences, healthcare, and bioinformatics industries. These Drug Discovery conferences focus on a range of areas, including but not limited to drug delivery, pharmacology, organic synthesis, structural biology, and medicinal chemistry. They also highlight great achievements in preparing cardiovascular, anticancer, anti-infective, and CNS drugs.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson's disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced MagellanTM platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements
This release contains“forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as“believes,”“expects,”“anticipates,”“intends,”“will,”“may,”“should,” or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company's current or future product candidates including GT-02287; expectations regarding the completion, quality and timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including the dose extension study; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company's product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the Company's Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.

Investors:
Gain Therapeutics, Inc.
Apaar Jammu
Manager, Investor Relations and Public Relations
...

LifeSci Advisors LLC
Chuck Padala
Managing Director
...

Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
...
...
(760) 846-9256

MENAFN23092025004107003653ID1110098845